Pre-made Tigatuzumab benchmark antibody ( Whole mAb, anti-TNFRSF10B/TRAIL-R2 therapeutic antibody, Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-571

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-571 Category Tag

Product Details

Pre-Made Tigatuzumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.

Products Name (INN Index)

Pre-Made Tigatuzumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody

INN Name

Tigatuzumab

Target

TNFRSF10B

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2007

Companies

Daiichi Sankyo Company,University of Alabama at Birmingham

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Breast cancer,Colorectal cancer,Liver cancer,Lymphoma,Non-small cell lung cancer,Ovarian cancer,Pancreatic cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TNFRSF10B

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide